中风补血引接方配合抗血小板药物对急性缺血性脑血管病病人血清HIF-1α、copeptin、Caspase-3的影响

Influence of Zhongfeng Buxue Yinjie Prescription and Antiplatelet Drugs on the Serum HIF-1,Copeptin,and Caspase-3 in Acute Ischemic Cerebrovascular Disease

目的观察中风补血引接方配合抗血小板药物对急性缺血性脑血管病(AICD)病人血清低氧诱导因子-1α(HIF-1α)、和肽素(copeptin)、半胱氨酸蛋白酶-3(Caspase-3)的影响。方法选取上海市金山区亭林医院收治的AICD病人86例作为研究对象,按照随机数字表法分为观察组和对照组,各43例。两组均给予基础治疗,对照组给予抗血小板药物治疗,研究组在对照组的基础上给予补血引接方治疗,两组均持续治疗2周。观察两组治疗前后中医证候积分、美国国立卫生研究院卒中量表(NIHSS)评分、血液流变学指标及血清HIF-1α、copeptin、Caspase-3水平,评价两组临床疗效。结果治疗后两组中医证候积分较治疗前显著降低(P<0.05),且研究组显著低于对照组(P<0.05);治疗后两组NIHSS评分较治疗前显著降低(P<0.05),且研究组显著低于对照组(P<0.05);治疗后两组纤维蛋白原(FIB)、全血低切黏度(LBV)、血浆黏度(PV)、红细胞比容(HCT)及血小板聚集率(PAR)均较治疗前显著降低(P<0.05),且研究组显著低于对照组(P<0.05);治疗后两组血清HIF-1α、copeptin及Caspase-3水平均较治疗前显著降低(P<0.05),且研究组显著低于对照组(P<0.05);治疗后研究组临床疗效总有效率显著高于对照组(P<0.05)。结论中风补血引接方配合抗血小板药物治疗AICD可改善病人血清HIF-1α、copeptin、Caspase-3水平,提高临床疗效。

Objective To explore the influence of Zhongfeng Buxue Yiejin prescription (ZBYP) and antiplatelet drugs on serum hypoxia inducible factor-1α(HIF-1α),copeptin,and cysteine protease-3 (Caspase-3) in patients with acute ischemic cerebrovascular disease (AICD). Methods Eighty six patients with AICD in our hospital were selected as the study objects,and were divided into observation group and control group according to random number table method,43 cases in each group. All patients in the two groups were given basis treatment,and the patients in control group were given antiplatelet therapy,and patients in the observation group were given ZBYP on the basis of the control group for two weeks. Traditional Chinese medicine (TCM) syndrome scores,National Institutes of Health Stroke Scale (NIHSS) score,blood rheology indexes and serum HIF-1α,copeptin,and Caspase-3 levels were observed,and clinical efficacy was evaluated in the two groups. Results After treatment,TCM syndrome scores were significantly lower than those before treatment in the two groups ( P <0.05),which were significantly lower in the observation group than those in the control group ( P <0.05). After treatment,NIHSS score was significantly lower than that before treatment in the two groups ( P <0.05),which was significantly lower in the observation group than that in the control group ( P <0.05). After treatment,fibrinogen,low shear blood viscosity,plasma viscosity,hematocrit and platelet aggregation rate were significantly lower than those in the two groups before treatment ( P <0.05),which were significantly lower in the observation group than those in the control group ( P <0.05). After treatment,serum HIF-1α,copeptin and caspase-3 levels were significantly lower than those before treatment ( P <0.05),which were significantly lower in the observation group than those in the control group ( P <0.05). After treatment,total effective rate was significantly higher in the observation group than that of the control group ( P <0.05). Conclusion ZBYP and antiplatelet drugs can improve serum HIF-1α,copeptin and caspase-3 levels in patients with of AICD,can improve clinical efficacy.